Skip to main content
OpenTrials
Completed

NCT Number: NCT03514069

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

The purpose of this study is to test how well the drug works, safety and tolerability of an investigational drug called Ruxolitinib in gliomas and glioblastomas, when combined with standard treatment for brain cancer, temozolomide and radiation.

Ruxolitinib is an experimental drug that works by targeting proteins in cells and stops them from growing. Ruxolitinib is experimental because it is not approved by the Food and Drug Administration (FDA) for the treatment of gliomas or glioblastomas

Temozolomide works by damaging the DNA of tumor cells so that they cannot divide properly. Some tumor cells can repair that damage and therefore be resistant to temozolomide.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glioma Astrocytoma Glioblastoma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Cleveland, Ohio, 44195, United States

About this study

Primary Objective

Arm 1:

To determine Maximum tolerated dose (MTD) of ruxolitinib with radiation (2 Gy x 30) in patients with unmethylated MGMT high-grade glioma (HGG)

Arm 2:

To determine Maximum tolerated dose (MTD) of ruxolitinib with radiation (2 Gy x 30) and daily temozolomide at 75 mg/m2 in patients with methylated MGMT high-grade glioma (HGG)

Secondary Objective(s)

Arm 1:

  • Safety of combination of ruxolitinib with radiation
  • Progression free survival (PFS)
  • Overall survival (OS)

Arm 2:

  • Safety of combination of ruxolitinib with radiation and temozolomide
  • Progression free survival (PFS)
  • Overall survival (OS)

STUDY DESIGN

A phase 1 design will be used with cohorts of 3 patients treated at each dose level in both arms 1 and 2 and monitored for treatment-related toxicities. Escalation to the next dose will proceed in the absence of dose-limiting toxicities (DLTs).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Arm 1:

  • Patients must have unmethylated MGMT supratentorial high-grade glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed astro oligodendroglioma or glioblastoma).

Arm 2:

  • Patients must have supratentorial methylated MGMT high-grade glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed astro oligodendroglioma or glioblastoma).

Both:

  • Patients must have MRI or CT with contrast within 28 days prior to starting treatment.
  • Patients must have a Karnofsky performance status ≥ 70% (i.e. the patient must be able to care for himself/herself with occasional help from others).
  • Patients must have adequate blood, kidney and liver function
  • Patients must be able to provide written informed consent.
  • Patients and their sexual partners must agree to avoid conception while on the study due to possible risks from experimental drugs. Women will need a negative pregnancy test to be on the study
  • Patients may not have any other cancers except skin cancer and localized bladder, prostate, cervical, or breast cancer which were cured more than 3 years ago

Exclusion criteria

  • Patients with other serious diseases
  • Pregnant women
  • Patients getting other cancer treatments
  • Patients with other cancers except for localized skin cancer and localized bladder, prostate, cervical, or breast cancer which were cured more than 3 years ago
  • Patients who have had repeat craniotomy for tumor therapy after receiving radiation therapy and temozolomide treatment.
  • Patients who have previously received other treatments for their cancers
  • Patient has previously taken ruxolitinib or is allergic to components of the study drug
  • Use of blood thinners
  • Human immunodeficiency virus (HIV) infection
  • Active hepatitis B or C infection
  • Heart diseases including abnormal electrocardiogram (EKG)
  • Patients unwilling or unable to follow this protocol

Treatment and study plan

Ruxolitinib

Drug

Starting dose ruxolitinib 10 mg twice daily

Radiation

Radiation

60gy for 6 weeks

Temozolomide

Drug

75mg/m2

Primary outcomes

  1. Maximum tolerated dose (MTD) of ruxolitinib with radiation in study patients

    Time frame: Up to 6 weeks

  2. Maximum tolerated dose (MTD) of ruxolitinib with radiation and daily Temozolomide in study patients

    Time frame: Up to 6 weeks

Secondary outcomes

  1. Number of patient study specific adverse events as a measure of safety

    Time frame: Up to 8 weeks after beginning treatment

    Study specific adverse events are defined as any of the following events occurring during the first 8 weeks of treatment with ruxolitinib and while being given radiation/temozolomide: grade 3 or 4 low platelets, grade 4 low red blood cells, grade 4 low white blood cells lasting more than a week, fever, any non-blood related side effect of grade 3 or greater (excluding hair loss) despite treatment, grade 4 radiation-related skin changes, and any episode of noninfectious pneumonitis.

  2. Number of patients who have experienced progression free survival as defined by the response assessment in neuro-oncology (RANO) criteria

    Time frame: Up to 6 weeks

  3. Average time patients stayed alive on study

    Time frame: Up to 6 weeks

Sponsors and collaborators

Lead sponsor

Case Comprehensive Cancer Center

Other

Registry information

Official study title

Phase I Study of Ruxolitinib With Radiation and Temozolomide in Patients With Newly Diagnosed Grade III Gliomas and Glioblastoma

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
May 2, 2018
Registry last updated
Jun 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.